There were 285 new cases of measles in the U.S. in 2024. Measles, also known as rubeola, is an infectious disease that is highly contagious and affects mostly children. Common symptoms of measles include fever, runny nose, sore throat, cough, and a rash. Although death rates from measles have decreased around the world, it is still responsible for around 81,000 deaths worldwide per year. Measles vaccination The main reason for the decrease in measles cases and deaths is due to high vaccination rates. The widely used MMR vaccine protects against measles, mumps, and rubella and is safe and effective. In 2023, around 91 percent of adolescents in the U.S. aged 13 to 17 years had received an MMR vaccination. However, in recent years there has been a rise in measles cases in many parts of the world due to vaccine hesitancy. Vaccine hesitancy Vaccine hesitancy refers to a refusal or reluctance to have children vaccinated, despite the overwhelming evidence that vaccines are safe and effective. This hesitancy comes from a misunderstanding of the ingredients in vaccines and how they work, a mistrust of doctors and pharmaceutical companies, and belief in the unfounded associations of vaccines with other diseases and disorders.
In 2024, there were a total of 285 cases of measles in the United States, with 120 of these cases among children aged under five years. From January 1 to March 6, 2025, there were 222 cases of measles. There were also two reported deaths from the disease during this time, the first since 2015. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2023, there were a total of 58 cases of measles in the United States. Around 72 percent of measles cases that year were attributed to unvaccinated individuals. Meanwhile, those with two doses of vaccination only accounted for just three percent of cases. This statistic shows the number of measles cases reported in the United States from 2020 to 2024, by vaccination status.
In 2023, there were around 58 measles cases in the United States, with 20 of these cases among those aged 5 to 19 years. This statistic shows the number of measles cases reported in the United States from 2020 to 2024, by age.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Forecast: Number of Reported Measles Cases in the US 2024 - 2028 Discover more data with ReportLinker!
In 1970, there were 22.79 new cases of measles per 100,000 population in the United States. However, this rate dropped to .08 in the year 2024. This statistic shows the number of new cases of measles per 100,000 population in the United States from 1919 to 2024.
In 2024, there were 285 measles cases in the United States. That year, Minnesota had the highest number of cases, followed by Illinois, and Oregon. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Forecast: Measles Incidence in the US 2024 - 2028 Discover more data with ReportLinker!
In 2024, there were a total of 285 cases of measles in the United States. Around 89 percent of these cases were among those who were unvaccinated or whose vaccination status was unknown. From January 1 to March 6, 2025, there were 222 cases of measles, with those who were unvaccinated or with an unknown vaccination status accounting for 94 percent of these cases. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2024, there were a total of 285 cases of measles in the United States. That year, around half of measles cases among children aged under five years were hospitalized for isolation or for management of measles complications. From January 1 to March 6, 2025, there were 222 cases of measles, with 28 percent of cases among children under five needing hospitalization. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2024, there were a total of 285 cases of measles in the United States. Around 40 percent of these cases were hospitalized for isolation or for management of measles complications. From January 1 to March 6, 2025, there were 222 cases of measles, with 17 percent needing hospitalization. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
A survey of adults in the United States from 2024 found that 23 percent of those with less than a college education thought it was definitely true or probably true that getting the measles vaccine is more dangerous than becoming infected with measles. However, this statement is false. Measles is a highly contagious disease that is especially dangerous for children. Vaccinations against measles are safe and effective and have resulted in a significant decrease in measles cases and deaths in the United States. Vaccine hesitancy and skepticism have been blamed for an increasing number of measles outbreaks lately.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 6.5(USD Billion) |
MARKET SIZE 2024 | 6.98(USD Billion) |
MARKET SIZE 2032 | 12.3(USD Billion) |
SEGMENTS COVERED | Vaccine Type ,Application ,Route of Administration ,End User ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increasing burden of infectious diseases Advancements in biotechnology Growing demand for personalized vaccines Government initiatives and funding Expansion of vaccination programs |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Merck ,Serum Institute of India ,Takeda Pharmaceutical Company ,AstraZeneca ,Novavax ,Moderna ,GlaxoSmithKline ,Bharat Biotech ,Pfizer ,Sanofi ,Abbott Laboratories ,Emergent BioSolutions ,Johnson & Johnson ,Bayer |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Increased Global Vaccination Demand Emerging Infectious Diseases Technological Advancements Government Initiatives and Expansion in Developing Regions |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.34% (2025 - 2032) |
A survey of adults in the United States from 2024 found that 23 percent of Republicans thought it was definitely true or probably true that getting the measles vaccine is more dangerous than becoming infected with measles. However, this statement is false. Measles is a highly contagious disease that is especially dangerous for children. Vaccinations against measles are safe and effective and have resulted in a significant decrease in measles cases and deaths in the United States. Vaccine hesitancy and skepticism have been blamed for an increasing number of measles outbreaks in recent years.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 3.1(USD Billion) |
MARKET SIZE 2024 | 3.24(USD Billion) |
MARKET SIZE 2032 | 4.6(USD Billion) |
SEGMENTS COVERED | Vaccine Type ,Packaging ,Application ,Age Group ,Distribution Channel ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising vaccination rates Increasing government initiatives Growing awareness of disease prevention Technological advancements and Expanding healthcare infrastructure |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | GlaxoSmithKline PLC ,Merck & Co. ,Johnson & Johnson ,Serum Institute of India Pvt. Ltd ,Novavax ,SeqirusneweraModerna Therapeutics ,AstraZeneca Plc ,Sanofi Pasteur ,Bavarian Nordic ,Janssen Vaccines ,Takeda Pharmaceutical Company Limited ,BioNTech ,CSL Limited ,Pfizer Inc. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | MMR Vaccine Shortage in Asia Pacific Africa Rising Incidence of Measles Cases Globally Government Initiatives for Vaccination Programs Increasing disposable income in developing countries Growing Awareness of Vaccine Importance |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.49% (2025 - 2032) |
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 1.67(USD Billion) |
MARKET SIZE 2024 | 1.75(USD Billion) |
MARKET SIZE 2032 | 2.5(USD Billion) |
SEGMENTS COVERED | Drug Class ,Route of Administration ,Disease Stage ,Chemotherapy Regimen ,Patient Population ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising cancer prevalence Technological advancements Development of novel therapies Increasing demand for personalized medicine Adoption of targeted therapies |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Oncovation Pharmaceuticals ,Novartis AG ,Daiichi Sankyo Company, Limited ,Axsome Therapeutics ,Sanofi SA ,Aprecia Pharmaceuticals LLC ,Protagonist Therapeutics ,Helsinn Healthcare SA ,Aprea Therapeutics ,Teva Pharmaceutical Industries Ltd. ,Zogenix, Inc. ,Strativa Pharmaceuticals ,Arsia Therapeutics ,Symphogen AG ,Eisai Co., Ltd. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Novel drug delivery systems Targeted therapies Improved patient care Rise in cancer incidence Personalized treatment plans |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.56% (2025 - 2032) |
A survey of U.S. adults from 2024 found that around 73 percent of respondents thought it was very accurate or somewhat accurate that there is no evidence of a link between measles vaccines and getting autism, as stated by the CDC. However, around a quarter of U.S. adults do not accept the CDC's statement that there is no evidence linking the measles vaccine to getting autism. Vaccinations against measles have resulted in significant decreases in cases and deaths from the disease in the United States. However, vaccine hesitancy and skepticism have been blamed for an increasing number of measles cases.
In the year 2000, there were around 3,397 deaths due to measles in Europe. This number dropped to just 222 in 2023. This statistic shows the estimated number of deaths due to measles worldwide in 2000 and 2023, by region.
In 2022, there were three reported cases of measles in Canada, compared to over two thousand cases in 1995. This statistic shows the number of reported cases of measles in Canada from 1930 to 2022.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
There were 285 new cases of measles in the U.S. in 2024. Measles, also known as rubeola, is an infectious disease that is highly contagious and affects mostly children. Common symptoms of measles include fever, runny nose, sore throat, cough, and a rash. Although death rates from measles have decreased around the world, it is still responsible for around 81,000 deaths worldwide per year. Measles vaccination The main reason for the decrease in measles cases and deaths is due to high vaccination rates. The widely used MMR vaccine protects against measles, mumps, and rubella and is safe and effective. In 2023, around 91 percent of adolescents in the U.S. aged 13 to 17 years had received an MMR vaccination. However, in recent years there has been a rise in measles cases in many parts of the world due to vaccine hesitancy. Vaccine hesitancy Vaccine hesitancy refers to a refusal or reluctance to have children vaccinated, despite the overwhelming evidence that vaccines are safe and effective. This hesitancy comes from a misunderstanding of the ingredients in vaccines and how they work, a mistrust of doctors and pharmaceutical companies, and belief in the unfounded associations of vaccines with other diseases and disorders.